- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04840758
Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer
A Prospective Single-arm Single-center Clinical Study:Assessment of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer (sMPLC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Deng Chong, MD
- Phone Number: 8605922139531
- Email: dengchongxm@163.com
Study Contact Backup
- Name: Jiang Jie, MD
- Phone Number: 8605922137271
- Email: jiangjiexm@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1.The diagnostic criteria for early sMPLC refer to the American College of Chest Physicians (ACCP) standard, and the following conditions should be met:
- CT showed the presence of at least three or more lesions(Pure glass or partially solid/solid)
- Proved to be different pathologic types by pathology.
c. If there is only one pathologically confirmed lesion or two pathological types are identical, the following conditions need to be met:
- . The lesions are located in different lobes
- . No mediastinal lymph node metastasis
- . distance metastasis free
2. At least two lesions were suitable for SABR treatment.
3. ECOG performance status 0-2.
4. Stable lab values: Hematological: Absolute neutrophil count (ANC) ≥1.5×109/L, Platelets ≥100×109/L, Hemoglobin ≥9 g/dL Renal: Creatinine OR Measured or calculated creatinine clearance (CrCl) (glomerular filtration rate [GFR] can also be used in place of creatinine or CrCl) ≤1.5× the upper limit of normal (ULN) OR ≥60 mL/min for patient with creatinine levels >1.5× institutional ULN Hepatic: Total bilirubin ≤1.5×ULN OR Direct bilirubin ≤ULN for patients with total bilirubin levels >1.5×ULN, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN OR ≤5×ULN for patients with liver metastases ,globulin≥20 g/L, albumin≥30 g/L.
5. Female subjects must have a negative urine or serum pregnancy test within 72 hours prior to taking study drug if of childbearing potential.
6. Able to understand and give written informed consent and comply with study procedures.
Exclusion Criteria:
- Previously received any T cell costimulation or immunological checkpoint treatment, including but not limited to CTLA-4 inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors or other T cell-targeting drugs.
- An active autoimmune disease requiring systemic treatment (such as the use of disease-alleviating drugs, corticosteroids or immunosuppressants) occurred within 2 years prior to the first administration.Alternative therapies (such as thyroxine, insulin or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic.
- Interstitial lung disease, drug-induced pneumonia, radiation pneumonitis requiring steroid therapy or active pneumonia with clinical symptoms or severe pulmonary dysfunction.
- Previous or current history of cancer other than NSCLC, except for non-melanoma skin cancer, in-situ cervical cancer or other cancers that have received curable treatment and have shown no signs of recurrence for at least 5 years.
- Have a tendency to hereditary bleeding or coagulopathy. Clinically significant bleeding symptoms or clear bleeding tendency within 3 months prior to enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood++ and above.
- There are clinical symptoms or diseases of the heart that are not well controlled, such as: (1) heart failure of NYHA class 2 or higher (2) unstable angina (3) myocardial infarction within 24 weeks (4) clinical need for treatment or Interventional supraventricular or ventricular arrhythmia.
- Uncontrolled hypertension after treatment (systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90mmHg), with a history of hypertensive crisis or hypertensive encephalopathy;Uncontrolled hyperglycemia after treatment (fasting glucose >8.9mmol/L).
- Have a history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency disease, or history of organ transplantation and bone marrow transplantation.
- Active hepatitis B (positive detection of hepatitis B virus surface antigen [HBsAg] in the screening period, and detection of HBV-DNA detection value higher than the upper limit of the normal value of the laboratory in the research center) or hepatitis C (in the screening period, hepatitis C virus surface antibody [ HCsAb] positive, HCV-RNA positive).
- Subjects who have received or will receive live vaccine within 30 days of the first treatment.
- Allergic reactions to test drugs for this application.
- The investigator determined that the subject had other factors that might lead to the termination of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SABR+Sintilimab
Stereotactic ablation radiotherapy (SABR) was performed sequentially on the primary and secondary lesions.
Sintilimab was used 2 weeks after the end of SABR.
Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles.
|
Stereotactic ablation radiotherapy was performed sequentially on the primary and secondary lesions.
50Gy/4F or 70Gy/10F were used according to the specific location of the tumor。
Sintilimab was started 2 weeks after the end of radiotherapy.
Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
abscopal effect rate
Time Frame: at the time point of 3 Months after completion of the combined treatment
|
A reaction produced following irradiation but occurring outside the zone of actual radiation absorption
|
at the time point of 3 Months after completion of the combined treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse events
Time Frame: up to approximately 1 year
|
AE,according to NCI-CTCAE V4.03 and immune-related (ir) RECIST
|
up to approximately 1 year
|
Progression-Free Survival (PFS)
Time Frame: up to approximately 1 year
|
PFS, defined as the time from treatment to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first.
|
up to approximately 1 year
|
Disease Control Rate (DCR)
Time Frame: up to approximately 1 year
|
Disease Control Rate(DCR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version.
1.1, and immune-related (ir) RECIST
|
up to approximately 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jiang jie, MD, First Affiliated Hospital of Xiamen University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XMYY-2020Y091
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Primary Lung Cancer
-
Ruijin HospitalSun Yat-sen University; Shanghai General Hospital, Shanghai Jiao Tong University... and other collaboratorsRecruitingMultiple Primary Lung CancerChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruiting
-
Royal Marsden NHS Foundation TrustImperial College London; Royal Brompton & Harefield NHS Foundation Trust; Institute... and other collaboratorsRecruitingLung Cancer | Lung Metastases | Indeterminate Pulmonary Nodules | Second Primary CancerUnited Kingdom
-
Peking University People's HospitalGuangzhou Burning Rock Medical Examination Institute Co., Ltd.Not yet recruitingLung Cancer | Non Small Cell Lung Cancer | Multiple Primary Lung Cancers
-
M.D. Anderson Cancer CenterCompletedAdvanced Cancer | Malignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
The First Affiliated Hospital of Guangzhou Medical...UnknownMultiple Primary Lung CancersChina
-
Ruijin HospitalThe First Affiliated Hospital of Nanchang University; Second Affiliated Hospital... and other collaboratorsRecruitingMultiple Primary Lung CancersChina
-
RenJi HospitalUnknownMultiple Primary NeoplasmChina
-
Fudan UniversityNot yet recruiting
-
M.D. Anderson Cancer CenterWithdrawnMalignant Neoplasms of Independent (Primary) Multiple Sites
Clinical Trials on Stereotactic Ablation Radiotherapy
-
Washington University School of MedicineTerminatedMetastatic Colorectal CancerUnited States
-
John SappRecruitingMyocardial Infarction | Ventricular Tachycardia | Heart Disease Structural DisorderCanada
-
Second Affiliated Hospital, School of Medicine,...UnknownRecurrent Hepatocellular Carcinoma | Stereotactic Body Radiotherapy | Microwave AblationChina
-
Amsterdam UMC, location VUmcRecruitingColorectal Cancer Metastatic | Liver Metastasis Colon CancerNetherlands
-
Jonggi ChoiActive, not recruitingHepatocellular CarcinomaKorea, Republic of
-
Mercy ResearchCompletedNasopharyngeal Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Salivary Gland Cancer | Paraganglioma of Head and Neck | Head and Neck Sarcoma | Chordoma of Head and Neck | Chondrosarcoma of Head and Neck | Angiofibroma of Head and NeckUnited States
-
Lawson Health Research InstituteOntario Institute for Cancer ResearchActive, not recruiting
-
Mediterranean Institute of OncologyUniversity of Palermo; University of MessinaRecruitingQuality of Life | Neurocognitive Deficit | Activities of Daily LivingItaly
-
The Netherlands Cancer InstituteCompletedLung Cancer | Metastatic Lung CancerNetherlands, United States, Canada, Germany
-
National Taiwan University HospitalUnknownMetastasis of Malignant Neoplasm to Lymph NodeTaiwan